The class of "IFN-α1 inhibitors" comprises compounds that can modulate the function and activity of IFN-α1, either directly or indirectly, through their influence on biochemical pathways and cellular processes that IFN-α1 is involved in. Ruxolitinib and Baricitinib, both JAK inhibitors, disrupt the signaling cascade initiated by IFN-α1, thereby reducing its biological activity. Dexamethasone, a synthetic glucocorticoid, interferes with the JAK-STAT pathway by reducing the expression of STAT1 and STAT2, critical transducers in the pathway, leadingto a decrease in IFN-α1 activity. Stattic and S3I-201, both specific inhibitors of STAT3, can also contribute to the reduction in IFN-α1 activity. While IFN-α1 primarily signals through STAT1 and STAT2, it can also activate STAT3. Thus, inhibiting this alternate pathway can further decrease its activity. Nifuroxazide, another potent STAT inhibitor, acts by inhibiting STAT1 and STAT2, leading to a reduction in IFN-α1's biological activity.
AG490, another member of this class, is a JAK2 inhibitor. Inhibiting JAK2, which is involved in IFN-α1 signal transduction, disrupts the signaling cascade and diminishes IFN-α1's biological activity. BAY 11-7082, an NF-κB inhibitor, indirectly reduces IFN-α1's activity. Although IFN-α1 does not directly activate NF-κB, the activation of NF-κB enhances IFN-α1 transcription. Hence, inhibiting NF-κB reduces IFN-α1's activity. On the other hand, AG-490, fludarabine, cyclosporine A, and hydroxyurea work by influencing DNA synthesis and gene transcription. AG-490 is a JAK2 inhibitor that disrupts the IFN-α1 signaling cascade, leading to a decrease in activity. Fludarabine, a purine analog, and hydroxyurea, a ribonucleotide reductase inhibitor, both inhibit DNA synthesis, which results in decreased expression of IFN-α1. Cyclosporine A, an immunosuppressive agent, inhibits the activity of calcineurin, which is involved in activating IFN-α1 transcription, leading to a decrease in IFN-α1's activity. Overall, these diverse compounds all serve to modulate the function and activity of IFN-α1 through various direct and indirect mechanisms.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $246.00 $490.00 $536.00 | 16 | |
Ruxolitinib is a Janus kinase (JAK) inhibitor. JAKs are integral components of the signaling pathway for many cytokines and growth factors, including IFN-α1. By inhibiting JAKs, Ruxolitinib can disrupt the signaling cascade initiated by IFN-α1, effectively reducing its biological activity. | ||||||
Baricitinib | 1187594-09-7 | sc-364730 sc-364730A | 5 mg 25 mg | $196.00 $651.00 | ||
Baricitinib is another JAK inhibitor. By preventing JAK activation, it can disrupt the signaling cascade initiated by IFN-α1, leading to reduced IFN-α1 activity. | ||||||
Dexamethasone | 50-02-2 | sc-29059 sc-29059B sc-29059A | 100 mg 1 g 5 g | $76.00 $82.00 $367.00 | 36 | |
Dexamethasone is a synthetic glucocorticoid that can interfere with the JAK-STAT pathway, a critical pathway for IFN-α1 signal transduction. Dexamethasone can reduce the expression of STAT1 and STAT2, the key transducers in the JAK-STAT pathway, leading to reduced IFN-α1 activity. | ||||||
Stat3 inhibitor V, stattic | 19983-44-9 | sc-202818 sc-202818A sc-202818B sc-202818C sc-202818D sc-202818E sc-202818F | 25 mg 100 mg 250 mg 500 mg 1 g 2.5 g 5 g | $127.00 $192.00 $269.00 $502.00 $717.00 $1380.00 $2050.00 | 114 | |
Stattic is a specific inhibitor of STAT3. While IFN-α1 primarily signals through STAT1 and STAT2, it can also activate STAT3. By inhibiting STAT3, Stattic can reduce the activity of IFN-α1. | ||||||
Nifuroxazide | 965-52-6 | sc-204128 sc-204128A | 500 mg 5 g | $199.00 $510.00 | 5 | |
Nifuroxazide is a potent STAT inhibitor. By inhibiting STAT1 and STAT2, the key transducers in the JAK-STAT pathway for IFN-α1, Nifuroxazide can reduce the biological activity of IFN-α1. | ||||||
Tyrphostin B42 | 133550-30-8 | sc-3556 | 5 mg | $26.00 | 4 | |
Tyrphostin B42 (AG490) is a JAK2 inhibitor. By preventing JAK2, which is involved in the signaling pathway of IFN-α1, AG490 can effectively reduce the biological activity of IFN-α1. | ||||||
Stat3 Inhibitor VI, S3I-201 | 501919-59-1 | sc-204304 | 10 mg | $148.00 | 104 | |
S3I-201 is a specific inhibitor of STAT3. By inhibiting STAT3, which can also be activated by IFN-α1, S3I-201 can reduce the activity of IFN-α1. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $61.00 $83.00 $349.00 | 155 | |
BAY 11-7082 is an NF-κB inhibitor. While IFN-α1 does not directly activate NF-κB, the activation of NF-κB can enhance the transcription of IFN-α1. By inhibiting NF-κB, BAY 11-7082 can indirectly reduce the activity of IFN-α1. | ||||||
Fludarabine | 21679-14-1 | sc-204755 sc-204755A | 5 mg 25 mg | $57.00 $200.00 | 15 | |
Fludarabine is a purine analog that inhibits DNA synthesis, leading to reduced expression of various genes, including IFN-α1. By inhibiting DNA synthesis, Fludarabine can indirectly reduce the activity of IFN-α1. | ||||||
Cyclosporin A | 59865-13-3 | sc-3503 sc-3503-CW sc-3503A sc-3503B sc-3503C sc-3503D | 100 mg 100 mg 500 mg 10 g 25 g 100 g | $62.00 $90.00 $299.00 $475.00 $1015.00 $2099.00 | 69 | |
Cyclosporine A is an immunosuppressive agent that can inhibit the activity of calcineurin. Calcineurin is involved in the activation of the transcription of IFN-α1. By inhibiting calcineurin, Cyclosporine A can indirectly reduce the activity of IFN-α1. | ||||||